Texas Dermatology

OCTOBER 20, 2023

However, it’s crucial to prioritize safety when applying makeup to your skin. In this blog, we’ll discuss Halloween makeup safety tips, what to do if you encounter a bad skin reaction, and why scheduling a dermatology appointment at Texas Dermatology is essential for addressing skin issues.

Makeup 36

Makeup Safety Skin Issues Irritation 36

The Dermatology Digest

JANUARY 5, 2024

Journey Medical Corporation has submitted a New Drug Application (NDA) to the U.S. The NDA submission is based on positive data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea. The post Rosacea Pipeline Watch: Journey Medical Submits NDA for DFD-29 appeared first on The Dermatology Digest.

Rosacea 36

Rosacea Medical Office Safety 36

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

Academic Alliance in Dermatology

FEBRUARY 13, 2024

At Academic Alliance in Dermatology, we understand the importance of using products that not only care for your skin on the surface but also work effectively at a cellular level. This is where medical-grade skincare like SkinCeuticals, ZO, Colorescience, Obagi, SkinMedica and Alastin distinctly outshine drugstore brands.

Medical Grade Skincare 36

Medical Grade Skincare Medical Skincare Skin Health 36

Academic Alliance in Dermatology

FEBRUARY 13, 2024

At Academic Alliance in Dermatology, we understand the importance of using products that not only care for your skin on the surface but also work effectively at a cellular level. This is where medical-grade skincare like SkinCeuticals, ZO, Colorescience, Obagi, SkinMedica and Alastin distinctly outshine drugstore brands.

Medical Grade Skincare 36

Medical Grade Skincare Medical Skincare Skin Health 36

The Dermatology Digest

NOVEMBER 18, 2024

Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. ” Comprehensive results from both ICONIC-LEAD and ICONIC-TOTAL are being prepared for presentation at upcoming medical congresses and will be shared with health authorities in planned submissions. achieving PASI-90.

Safety 36

Safety Innovations Dermatology Medical 36

The Dermatology Digest

JUNE 18, 2024

Permanent makeup can help restore confidence in people with certain skin and hair conditions, according to a new article in the Journal of the American Academy of Dermatology. In South Carolina, permanent makeup is regulated by the state’s medical board.

Permanent Makeup 36

Permanent Makeup Makeup Sanitation and Sterilization Dermatology 36

The Dermatology Digest

AUGUST 20, 2024

There are currently no other FDA-approved oral medications for moderate to severe plaque psoriasis in this patient population. The adverse events were consistent with the known safety profile of Otezla in adult patients. sPGA response for Otezla versus 10.8% for placebo (95% CI: 12.2%, 32.4%. For more information, visit Otezla.com.

Safety 74

Safety Injections Therapy Treatments 74

The Dermatology Digest

MARCH 18, 2024

If approved, we believe that DFD-29 will be the only oral medication to address both inflammatory lesions and erythema from rosacea, and will be a preferred treatment option by physicians and their patients to address the condition.”

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

APRIL 7, 2024

The new ladder divides nonsteroidal medication classes into treatments for exacerbations and maintenance therapies in an escalating order based on their increasing potential for adverse effects. Ch’en, a medical student at the Albert Einstein College of Medicine in the Bronx, New York, and Peter A. The study appears in Dermatitis.

Treatments 77

Treatments Dermatitis Therapy Medical 77

The Dermatology Digest

FEBRUARY 11, 2024

By Ted Rosen, MD According to the results of a recently published investigation in JAMA Dermatology 1 , the Janus kinase (JAK) inhibitors currently utilized for a variety of skin diseases appear safe in our dermatological population. Ireland PA, Jansson N, Spencer SKR. January 31, 2024. doi:10.1001/jamadermatol.2023.5509

Dermatology 74

Dermatology Safety Clinic Therapy 74

The Dermatology Digest

SEPTEMBER 9, 2024

Obagi Introduces Two New Elastiderm Products Obagi Medical is launching Elastiderm Lift Up & Sculpt Facial Moisturizer and Elastiderm Advanced Filler Concentrate. The post TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

The Dermatology Digest

JANUARY 29, 2024

The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of Zoryve (roflumilast) foam, 0.3% Zoryve foam was well-tolerated with a favorable safety and tolerability profile.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

FEBRUARY 2, 2024

New sunscreen ingredients are needed to help assuage patient safety concerns and lower skin cancer rates. Natural products such as algae and herb derivatives are also gaining traction, according to a new narrative review in the Journal of Integrative Dermatology. What’s New in ‘Natural’ Sunscreens?

Ingredients 74

Ingredients Safety Innovations Dermatology 74

The Dermatology Digest

SEPTEMBER 12, 2024

“The positive pivotal data from this study reinforce the potential of Dupixent to offer a new treatment option for the many people suffering from chronic spontaneous urticaria who do not respond to standard-of-care antihistamines,” says Dietmar Berger, MD, PhD, Chief Medical Officer, Global Head of Development at Sanofi, in a news release.

Safety 36

Safety Office Dermatology Medical 36

The Dermatology Digest

DECEMBER 20, 2023

Secondary measures of efficacy, as well as safety and pharmacokinetics, will also be assessed. Head of the SAB, Is a Professor of Dermatology with Penn State Health Hershey Medical Center, and Penn State College of Medicine. is a Professor of Dermatology and Director of Dermatologic Surgery at the University of Minnesota.

Dermatology 36

Dermatology Surgery Eczema Office 36

The Dermatology Digest

SEPTEMBER 20, 2024

Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s Secondary efficacy objectives include progression-free survival, overall survival and local control up to twelve months after treatment, and the safety objective is the measurement of any related adverse events. Dr. Robert B.

Office 74

Office Safety Clinic Medical 74

The Dermatology Digest

JUNE 12, 2024

The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals. The post Tox Update: Evolus Launches Nuceiva in Spain appeared first on The Dermatology Digest. Evolus, Inc. is rolling out Nuceiva (botulinum toxin type A) across Spain.

Safety 36

Safety Branding Facials Clinic 36

The Dermatology Digest

AUGUST 13, 2024

” The Crnic Institute study team is now overseeing a second trial testing the safety and efficacy of the JAK inhibitor relative to other medicines for treating the condition known as Down Syndrome Regression Disorder , and a third trial focused on children with Down syndrome is expected to start recruitment in late 2024. .”

Clinic 74

Clinic Safety Dermatitis Medical 74

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 104

Retinol Social Media Skincare Routine Skincare 104

The Dermatology Digest

FEBRUARY 14, 2024

“We are thankful to the patients and medical experts whose insights informed our clinical trials, which assessed nemolizumab’s ability to reduce the symptoms of itch and skin lesions. Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

North Dallas Dermatology Associates

NOVEMBER 1, 2023

After all, who wouldn’t want to be in the capable hands of a medical professional? While practitioners in medical spas and salons may offer discounted rates, there is often a concerning lack of specialized training. This added layer of safety provides peace of mind to patients.

Office 36

Office Safety Medical Training 36

The Dermatology Digest

SEPTEMBER 23, 2024

These trials evaluated the safety and efficacy of delgocitinib compared to cream vehicle. This news is testament to our dedication to making a fundamental difference for those who need us most in medical dermatology. Both trials met their primary and all secondary endpoints. with the same determination and dedication.”

Safety 36

Safety Eczema Dermatology Clinic 36

The Dermatology Digest

JANUARY 20, 2024

The study is designed to assess the safety, tolerability, and pharmacokinetics, of orally administered EVO756. The post Eye on Itch: Evommune Initiaties Phase I Study of EVO756 in CSU appeared first on The Dermatology Digest. ” More About EVO756 MRGPRX2 is most abundantly found on mast cells and peripheral sensory neurons.

Safety 74

Safety Office Dermatitis Dermatology 74

The Dermatology Digest

MAY 23, 2024

Kimball, MD, MPH, Beth Israel Deaconess Medical Center and Professor of Dermatology, Harvard Medical School, Boston, MA. “In The safety profile of bimekizumab was consistent with safety data seen in previous trials with no new observed safety signals. Responses were maintained to Week 48.

Sustainability 36

Sustainability Safety Clinic Dermatology 36

The Dermatology Digest

OCTOBER 9, 2024

ICP-488 demonstrated good tolerability and a favorable safety profile, with most treatment emergent adverse events (TEREs) and treatment-related adverse events (TRAEs) being mild or moderate. The post InnoCare’s TYK2 Performs Well in Phase II PsO Study appeared first on The Dermatology Digest. respectively, compared to 11.6%

Safety 36

Safety Clinic Treatments Management 36

US Dermatologt Partners

JUNE 1, 2024

1 In an interview with Dermatology Times, Lockshin explained how far we have come in oral treatment options for psoriasis, the future outlook, and patient populations that benefit most from orals. A study involving 245 patients showed significant improvements at 16 weeks, confirming its efficacy and safety in younger populations.6

Therapy 41

Therapy Injections Safety Management 41

The Dermatology Digest

MARCH 5, 2024

Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the second half of 2024. The post And Then There Were Six…FDA Green Lights Hugel’s Toxin for Glabellar Lines appeared first on The Dermatology Digest. and Europe.

Branding 74

Branding Injections Safety Facials 74

Texas Dermatology

NOVEMBER 22, 2024

Texas Dermatology offers cutting-edge laser hair removal technology, designed to deliver safe, effective and long-lasting results for the entire body. What Happens During Treatment At Texas Dermatology, laser hair removal begins with a consultation, so we can assess your skin type, hair color and medical history.

Hair Removal 36

Hair Removal Waxing Skin Types Technology 36

The Dermatology Digest

MAY 14, 2024

The American Skin Association’s (ASA) SPOTS (Sun Protection Outreach Teaching by Students) program will receive the inaugural 2024 Research Achievement Award in Community Education/Outreach at the upcoming 2024 Society for Investigative Dermatology (SID) Annual Meeting in Dallas, TX. ” ASA Chairman, Howard P.

Sun Protection 36

Sun Protection Partnerships Education Safety 36

The Dermatology Digest

OCTOBER 30, 2024

Grants of up to $35,000 will be awarded to promising projects in the field of clinical, biological or pharmacological research linked to dermatology. Ultimately, our aim is to improve public health outcomes and raise awareness about the critical importance of sun safety in our communities,” say Drs. Nahar and Huynh in a news release.

Sun Protection 36

Sun Protection Dermatology Safety Innovations 36

The Dermatology Digest

APRIL 18, 2024

The safety profile was similar across all three arms and overall, 88.9% The post Phase 2 Data: Extra-strength Jeuveau Smooths Frown Lines for Up to 6 Months appeared first on The Dermatology Digest. of adverse events were rated as mild and no serious adverse events were identified.

Safety 36

Safety Office Surgery Dermatology 36

The Dermatology Digest

AUGUST 14, 2024

Patients may be cured with simple injections of VP-315,” adds Jonathan Kantor, MD, a dermatologist and Mohs surgeon at Florida Center for Dermatology, which was the leading enrollment site for the clinical study. The Company also plans to submit the final Phase 2 data for presentation at future medical meetings.

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

The Dermatology Digest

MAY 8, 2024

The safety profile of subcutaneous nivolumab was consistent with the IV formulation. The pharmacokinetics, efficacy, and safety results from CheckMate -67T were presented at the American Society of Clinical Oncology (ASCO) 2024 Genitourinary Cancers Symposium. “An

Safety 36

Safety Therapy Dermatology Injections 36

The Dermatology Digest

SEPTEMBER 30, 2024

The OLE results continue to show that ESK-001 has the potential to safely and effectively inhibit the TYK2 target at the 40mg twice daily dose and deliver lasting benefits that improve over time with continued treatment,” says Dr. Jörn Drappa, Alumis’ Chief Medical Officer, in a news release.

Safety 36

Safety Clinic Sustainability Office 36

The Dermatology Digest

JANUARY 14, 2024

The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. Treatment with Zoryve foam significantly increased the odds of achieving a meaningful improvement in quality of life at Weeks 2, 4, and 8, compared to vehicle as measured by the Dermatology Life Quality Index (DLQI), the study showed.

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

NOVEMBER 6, 2024

” The TBA recipients include: Innovating Pain and Fatigue Management Cynthia Aranow, MD, The Feinstein Institutes for Medical Research Dr. Aranow will evaluate the use of a new, non-toxic, non-painful device that stimulates the vagus nerve to reduce pain and fatigue in people with SLE.

Hospital 36

Hospital Therapy Management Networking 36